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The Transradial Approach to
Percutaneous Coronary Intervention
Historical Perspective, Current Concepts, and Future Directions
Sunil V. Rao, MD,* Mauricio G. Cohen, MD,† David E. Kandzari, MD,‡
Olivier F. Bertrand, MD, PHD,§ Ian C. Gilchrist, MD
Durham, North Carolina; Miami, Florida; La Jolla, California; Quebec City, Quebec, Canada;
and Hershey, Pennsylvania
Periprocedural bleeding complications after percutaneous coronary intervention (PCI) are associated with in-
creased short- and long-term morbidity and mortality. Although clinical trials have primarily assessed pharmaco-
logical strategies for reducing bleeding risk, there is a mounting body of evidence suggesting that adoption of a
transradial rather than a transfemoral approach to PCI may permit greater reductions in bleeding risk than have
been achieved with pharmacological strategies alone. However, despite a long history of use, a lack of wide-
spread uptake by physicians coupled with the technological limitations of available devices has in the past con-
fined transradial PCI to the status of a niche procedure, and many operators lack experience in this technique.
In this review, we examine the history of the transradial approach to PCI and discuss some of the circumstances
that have hitherto limited its appeal. We then review the current state of the peer-reviewed literature supporting
its use and summarize the unresolved issues affecting broader application of this technique, including lack of
operator familiarity and an insufficient evidence base for guiding practice. Finally, we describe potential direc-
tions for future investigation in the transradial realm. (J Am Coll Cardiol 2010;55:2187–95) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.039e
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aercutaneous coronary intervention (PCI) is an integral part
f treatment for ischemic heart disease. Coupled with
vidence-based pharmacological strategies, the use of PCI
n appropriate patients reduces morbidity and mortality
cross the spectrum of risk (1). Continual evolution of
ntithrombotic therapy and device technology has resulted
n the application of PCI to a wider population of patients
2). Procedural success rates are high and ischemic compli-
ations relatively rare (3); thus, attention has turned to
eriprocedural bleeding complications (4). Considerable
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010, accepted January 5, 2010.vidence suggests that post-PCI bleeding is associated with
n adverse prognosis (5). Clinical trials evaluating new
harmacological strategies have focused on reducing this
isk (6,7); however, absolute reductions in bleeding risk have
een modest across most studies. A growing body of
vidence suggests that a procedural strategy—using the
ransradial rather than the transfemoral approach for
CI—is associated with comparatively larger reductions in
leeding complications than those achieved with any anti-
oagulant strategy. In this review, we provide historical
erspective on the transradial approach, examine current
iterature supporting its use, and summarize unresolved
ssues and areas for future investigation.
ransradial PCI: Historical Perspective
lthough the transfemoral approach to cardiac catheter-
zation has dominated the explosive growth of invasive
ardiology in past decades, transradial access appeared
arly in the development of cardiac catheterization tech-
iques. In 1948, Radner (8) published one of the first
escriptions of transradial central arterial catheterization
nd attempts at coronary artery imaging using radial
rtery cut-down and 8- to 10-F catheters. Despite early
nthusiasm for the transradial approach, limitations of
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Transradial Approach for PCI May 18, 2010:2187–95contemporary equipment resulted
in a shift to larger vessels such as
the brachial, carotid, and femoral
systems for most catheter-based
procedures, and the radial artery
was relegated to use as a site for
monitoring arterial pressure.
In the late 1970s, percutane-
ous coronary angioplasty was in-
troduced using predominantly
9-F guiding catheters (9). Build-
ng on reports of successful transradial angiography from
anada in 1989 (10), Kiemeneij and Laarman (11) first
eported on the transradial approach for coronary stenting
n 1993. Given observed reductions in periprocedural bleed-
ng and reported improvements in patient comfort with this
pproach, a few enthusiastic early adopters emerged, but the
ransradial approach generally remained a niche technique.
As experience with the transradial approach grew, the
ack of severe access-site complications when compared with
he transfemoral approach was repeatedly demonstrated in
mall observational studies. A “learning curve” for develop-
ng proficiency in transradial procedures was noted (12),
ost-effectiveness was demonstrated (13,14), and small
ingle-center or limited multicenter randomized compari-
ons to femoral (with or without vascular closure devices)
nd brachial approaches (15,16) showed the superiority of
ransradial procedures with respect to vascular access site
omplications, speed of post-procedural recovery, and pa-
ient preference. The safety of transradial PCI in patients
herapeutically anticoagulated with warfarin (17) and the po-
ential for same-day coronary revascularization were described
18). In addition, transradial techniques have been expanded to
eripheral arterial interventions, including carotid (19), super-
cial femoral (20), mesenteric (21), and renal (21,22) arteries,
s well as for pediatric percutaneous procedures (22).
As we summarize below, the future adoption of transra-
ial PCI in the U.S. and other countries with low penetra-
ion of transradial techniques will depend on the generation
f high levels of evidence that confirm advantages seen in
maller observational and randomized studies, the availabil-
ty of training programs, commitment from operators and
rofessional societies, and comparative effectiveness data
hat demonstrate not only better clinical outcomes com-
ared with the transfemoral approach, but also better
conomic outcomes, such as cost savings or cost-
ffectiveness, and acceptable safety as it pertains to radiation
ose and exposure.
rocedural and Clinical Outcomes
fter Transradial PCI
hen comparing the transradial with the traditional trans-
emoral route for PCI, the discussion must include compar-
sons of procedural success, fluoroscopy times, and bleeding/
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CI  confidence interval
LOS  length of stay
OR  odds ratio
PCI  percutaneous
coronary interventionascular complications. nrocedural success and procedure time. In a systematic
verview of 12 randomized trials (n  3,224) comparing
adial and femoral approaches for diagnostic (7 studies) and
nterventional (5 studies) procedures, Agostoni et al. (23)
eported significantly higher rates of procedural failure for
ransradial access (odds ratio [OR]: 3.30; 95% confidence
nterval [CI]: 1.63 to 6.71) . When compared with earlier
tudies included in the analysis, more contemporary trials
emonstrate no differences in procedural failures between
reatment strategies, likely reflecting advances in both tech-
ique and technologies, including vasodilator pharmacology
nd hydrophilic catheters. However, the composite outcome
f death, myocardial infarction, emergency repeat revascu-
arization, or stroke did not statistically vary between
roups. Mann et al. (15) reported a single-center observa-
ional study comparing the transradial with the transfemoral
pproach in which the Perclose (Abbott Vascular, Santa
lara, California) femoral closure device was used. Proce-
ural success, complications, post-procedural length of stay
LOS), and percentage of patients discharged the same day
ere similar across groups; however, total procedure time
as significantly longer in the femoral group (57  22 min
emoral vs. 44  22 min radial, p  0.01) because of time
eeded to deploy the closure device.
The largest observational study to compare procedural
uccess rates between radial and femoral approaches used
ata from the National Cardiovascular Data Registry
593,094 procedures; 606 institutions) (24). Although radial
pproaches represented a modest proportion (1.32%) of case
olume, risk-adjusted procedural success (defined as residual
tenosis 50% and reduction in stenosis 20% with TIMI
ow grade 2) did not differ between access methods (OR:
.02; 95% CI: 0.92 to 1.12). In contrast, a more recent
ystematic overview (23 trials; 7,000 patients) by Jolly
t al. (25) found that the radial approach was associated with
trend toward a higher rate of inability to cross the lesion
ith a wire, balloon, or stent, compared with the femoral
pproach (Fig. 1).
Although overall procedural time may be similar between
ethods, radial access has been associated with modest but
tatistically significant increases in fluoroscopic time.
mong 420 patients undergoing diagnostic coronary an-
iography and percutaneous revascularization, procedural
uration and fluoroscopic time were significantly longer for
adial compared with femoral procedures, corresponding to
ignificantly higher radiation exposure for operators and
atients (26), although there was significant variability
mong operators. In the meta-analysis by Agostoni et al.
23), fluoroscopy time was significantly lower in the femoral
ohort (7.8 min vs. 8.9 min, p  0.001) . Similarly, in the
ational Cardiovascular Data Registry, radial PCI had
onger fluoroscopy time (13.5 min vs. 11.3 min, p 
.01), but there was no significant difference in total
olume of contrast used (24). Many of these studies did
ot correct for potential improvements in procedure and
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May 18, 2010:2187–95 Transradial Approach for PCIuoroscopy times that may be realized with greater
ransradial experience.
In general, it seems that increasing experience with the
ransradial approach is associated with decreased rates of
rocedure failure. In one observational study, an annual
rocedural volume 80 transradial cases correlated with
ignificant reductions in access failure, sheath insertion
ime, and overall procedural time (Fig. 2) (27). Similarly,
ther trials demonstrate an initial difference in procedural
Figure 1 Association Between Vascular Access Site for PCI an
Pooled analysis of 23 randomized trials (n  7,020) comparing the association be
(PCI) and procedure failure, access site crossover, death, the composite of death, str
Figure 2 Radial Volume and Outcomes
Relationship between operator volume of transradial percutaneous coronary
intervention over a 15-month period and procedure duration (min, solid dia-
monds), procedure failure (%, open circles), and sheath insertion time (min,
solid circles). Reprinted from Spaulding et al. (27).mime between radial and femoral cases that resolved by trial
ompletion as operator experience improved (12,16,23,28).
olly et al. (25) demonstrated that among operators who
referred the radial route, there was no significant difference
n successful lesion crossing (adjusted OR: 1.18; 95% CI:
.77 to 1.81; p  0.44); among less experienced operators,
here was a strong trend toward higher failure rates (ad-
usted OR: 3.47; 95% CI: 0.91 to 13.21; p  0.07) (25).
leeding and vascular outcomes. Bleeding complications
fter PCI are most commonly related to vascular access site
Figs. 3 and 4) and are associated with an increased risk of
ost-PCI morbidity and mortality (4,5,29,30). A consistent
ody of observational and small randomized studies sup-
orts an advantage of the transradial approach in reducing
CI-related hemorrhagic complications compared with the
ransfemoral approach (24,25). In the National Cardiovas-
ular Data Registry, the radial approach was associated with
significant reduction in bleeding complications that was
ore pronounced in certain high-risk subgroups, such as
omen and patients with acute coronary syndromes (ACS)
24). These findings are consistent with those of other
tudies evaluating the safety of a radial approach regarding
ignificantly reduced bleeding events, especially among
CS patients (31), those receiving more potent antithrom-
otic agents (32), and elderly patients (33). Jolly et al. (25)
ound that the transradial approach was associated with a
3% reduction in major bleeding compared with the trans-
emoral approach (Fig. 1). The radial approach may also
fford advantages in patients with peripheral arterial disease
nd/or obesity, in whom the femoral artery may be difficult
o access and compress manually due to body habitus.
owever, less experienced transradial operators should
robably avoid these challenging patients until they gain
comes
radial versus femoral approaches for percutaneous coronary intervention
myocardial infarction (MI), and major bleeding. Adapted from Jolly et al. (25).d Out
tween
oke, orore experience.
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Transradial Approach for PCI May 18, 2010:2187–95When vascular complications do occur after transradial
CI, they consist mainly of early and late radial artery
cclusion (34). Rarely, instances of radial artery eversion or
erforation (35), chronic regional pain syndrome (36), and
orearm hematoma or compartment syndrome (37) have
een described. There are no published reports of hand
schemia occurring after transradial PCI, which may be due
o avoidance of the radial approach in patients with a
ositive Allen test result or reporting bias. Post-PCI radial
rtery occlusion may be reduced by using smaller diameter
atheters and anticoagulation, and by avoiding prolonged
igh-pressure compression of the radial artery after arterial
heath removal. Two clinical trials have examined the role of
patent hemostasis,” or allowing antegrade flow in the radial
rtery during hemostatic compression at the occurrence of
adial occlusion. In one study, compression was guided by
ean arterial pressure (the pressure applied was equal to the
ean arterial pressure) versus usual compression (38). The
ncidence of radial occlusion at 24 to 72 h was 1.1% in the
ean arterial pressure–guided group and 12.0% in the usual
are group (p  0.0001). In the other trial, patients were
andomized to either compression that allowed antegrade
ow in the radial artery (Table 1) or usual care (39). Again,
he incidence of radial occlusion at 24 h and 30 days was
ignificantly reduced (24 h: 5.0% patent hemostasis group
s. 12.0% usual care, p  0.05; 30 days: 1.8% vs. 7%, p 
.05).
Studies have also found an association between the
eduction in bleeding events with transradial PCI and an
Figure 3 Site of Bleeding Complications in an Unselected Coho
Overall rate of Thrombolysis In Myocardial Infarction (TIMI) major (maj) bleeding 
CVA  cerebrovascular accident (ischemic stroke); GI  gastrointestinal bleeding;mprovement in clinical outcomes such as death and myo- pardial infarction. In the PRESTO ACS (Comparison of
arly Invasive and Conservative Treatment in Patients
ith Non–ST-Elevation Acute Coronary Syndromes) vas-
ular substudy, for example, the radial approach was asso-
iated with a significant decrease in bleeding complications
ompared with the femoral approach during hospitalization
0.7% vs. 2.4%; p  0.05), as well as a significant reduction
n 1-year death or recurrent infarction (5.5% vs. 9.9%; p 
.05) (31). Among procedural and clinical outcomes data
ollected for 38,872 PCI patients (radial approach, 20.5%)
ncluded in the British Columbia Cardiac Registry, radial
ccess for PCI was associated with a significantly lower rate
f post-procedural blood transfusion (1.4% vs. 2.8%, p 
.01) and a significant decrease in 30-day (OR: 0.71; 95%
I: 0.61 to 0.82) and 1-year mortality compared with
emoral access (40). In contrast, Jolly et al. (25) found no
ignificant association between the radial approach and
educed 1-year mortality (Fig. 1). An important limitation
f these data should be noted, however; most of these
tudies are either observational (and subject to confounding)
r are from small randomized trials conducted at centers
ith operators proficient in the radial approach. The chal-
enges of translating the potential advantages of the radial
pproach seen in these studies to the interventional com-
unity at large are discussed in the following.
ransradial Approach and Economic Outcomes
s noted previously, the most common complication in
Patients Undergoing PCI
overall rate of TIMI minor (min) bleeding  12.7%.
retroperitoneal hemorrhage. Adapted from Kinnaird et al. (30).rt of
5.4%;
RP atients undergoing PCI via transfemoral access relates to
2191JACC Vol. 55, No. 20, 2010 Rao et al.
May 18, 2010:2187–95 Transradial Approach for PCIFigure 4 Sites of Bleeding in PCI Trials
Rates of overall and access-site related bleeding in a sample of percutaneous coronary intervention clinical trials (REPLACE-2 [Randomized Evaluation in PCI Linking
Angiomax to Reduced Clinical Events 2] and ESPRIT [European/Australasian Stroke Prevention in Reversible Ischaemia Trial]) (A); non–ST-segment elevation acute coro-
nary syndrome trials (PARAGON [Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network] A, PARAGON B,
GUSTO [Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries] IIb non–ST-segment elevation cohort, PURSUIT [Platelet Gly-
coprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy], and SYNERGY [Superior Yield of the New Strategy of Enoxaparin, Revascularization
and GlYcoprotein IIb/IIIa inhibitors]) (B); and ST-segment elevation myocardial infarction clinical trials (GUSTO 1, GUSTO IIb ST-segment elevation cohort, GUSTO 3,
HERO-2 [Hirulog Early Reperfusion Occlusion], ASSENT-2 [Assessment of the Safety of a New Thrombolytic]) (C). bld  bleed.
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Transradial Approach for PCI May 18, 2010:2187–95he vascular access site. These complications are also asso-
iated with increased LOS and costs (24,41,42). Dedicated
ost analyses comparing vascular access sites have consis-
ently shown a significant reduction in hospital costs with
ransradial access. In a randomized study of patients under-
oing diagnostic catheterization, Cooper et al. (14) showed
hat transradial access was associated with a median cost
eduction of approximately $290/case driven by lower bed
ost, including nursing utilization, and decreased pharmacy
osts . A subsequent study comparing diagnostic catheter-
zation via transradial versus transfemoral access with clo-
ure devices showed that, despite comparable recovery
imes, total costs were still significantly lower with transra-
ial access (transradial $369.50  $74.60 vs. transfemoral
446.90  $60.20 vs. transfemoral with closure devices
553.40 $81.00) (43). In a small randomized study of 142
atients undergoing PCI for ACS, post-procedural LOS
as reduced by approximately 1.5 days and total hospital
harges were decreased from $23,389 to $20,476 with
ransradial access (44). A study comparing stenting via
ransradial and transfemoral access with a suture closure
evice showed a comparable LOS with both strategies at the
xpense of higher cost and complication rates in the
ransfemoral group (15).
There is also evidence that nursing workload can be
ignificantly reduced when the transradial approach is
ystematically used. In one single-center study, the time
pent to care for patients after PCI can be reduced from
74 min with transfemoral access to 86 min with tran-
radial access. In addition, nursing time outside the
atheterization laboratory on the medical ward was also
educed from 720 min with transfemoral access to 386
in with transradial access (45).
We note, however, that these studies are small and
onducted in limited numbers of centers where practice
atterns may have influenced both costs and cost savings.
hether these advantages are widely applicable needs
urther study in larger multicenter randomized trials.
nresolved Issues and Future Directions
he data summarized here illustrate several advantages of
atent Hemostasis Techniqueor Post-Procedural H mostasisTable 1 Patent Techniquefor Post-Procedural Hemostasis
1. Apply hemostasis device (e.g., HemoBand, RAD-Stat, TR-Band) to wrist
2. Place pulse oximeter on ipsilateral index finger or thumb
3. Tighten hemostasis device and remove sheath
4. Occlude ipsilateral ulnar artery
5. Loosen hemostasis device until plethysmographic signal returns or bleeding
occurs
If bleeding occurs, use manual compression
If hemostasis is maintained in the presence of the plethysmographic signal,
then leave hemostasis device in place for 2 h
6. Check for maintenance of plethysmographic signal every hour
dapted from Pancholy et al. (39).he transradial versus the transfemoral approach to PCI. *lthough these data strongly support use of the transradial
pproach as the default method for coronary intervention, it
s also important to review several limitations of this
echnique and the data supporting it (Table 2). These
imitations relate broadly to practical issues (training and
xperience of operators and catheterization laboratory staff),
atient issues (previous coronary artery bypass grafting,
hallenging forearm and chest arterial anatomy), technical
ssues (e.g., limitation in the size of the guide catheter that
an be used, potentially increased procedure times and
adiation exposure), and gaps in evidence (lack of large
ulticenter randomized data on efficacy and safety). Impor-
antly, changing practice from the transfemoral to the
ransradial approach will, in most cases, result in increased
ontrast use and radiation exposure to operator and patient
arly in the learning curve. Table 3 lists selected transradial
rocedural challenges and outlines strategies for addressing
hem.
There is scant discussion of the transradial approach in
urrent published training guidelines. Although there is a
inimum number of diagnostic and interventional cases
ecommended for fellows undergoing interventional train-
ng, no minimum number of transradial cases is specified
notably, no minimum of femoral or brachial cases is
pecified either) (46). The obvious result is the continuous
roduction of cardiovascular specialists without training or
ven exposure to transradial PCI during fellowship. Cur-
ently, there are no transradial training programs supported
y the major cardiovascular professional societies; there are,
owever, a limited number of courses supported by industry.
his lack of systematic training leads to the transradial PCI
eing viewed as a niche procedure, a fact underscored by
ata from large registries showing that the radial approach
ccounts only for 1.3% of all PCI procedures in the U.S.
24). This ultimately affects both the quality of care pro-
ided to the majority of PCI patients as well as the quality
f studies examining the relative merits of transradial PCI
see the following text).
dvantages and Disadvantagesf Transradi l Approach to PCITable 2 A vant ges and Disadvantagesof Transradial Approach to PCI
Advantages
Reduced bleeding risk
Reduced length of stay and costs
Early ambulation
Improved patient comfort
Obviates discontinuation of oral anticoagulant therapy
Same-day discharge possible
Disadvantages
Learning curve
Not routinely taught in fellowship programs
Limits guide catheter size
Possible greater radiation exposure to operator*
Long-term consequences to radial artery (e.g., for re-access or for use as
bypass graft) unknownMay be a function of operator experience.
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May 18, 2010:2187–95 Transradial Approach for PCIA related issue is patient-specific factors that remain
hallenging in the transradial context. These include diffi-
ulties in accessing the radial artery, traversing the radial/
rachial/subclavian arterial anatomy, achieving adequate
uiding catheter support, and performing transradial cath-
terization and PCI using the left radial artery in patients
ho have undergone previous coronary artery bypass graft-
ng (47). All of these challenges can increase procedure time
nd radiation exposure to both operator and patient, but can
e addressed with adequate operator experience (12). These
imitations are offset by the advantages offered to patients
Table 2). Operator experience can be positively influenced
hrough formal training programs and a commitment to
ransradial PCI in daily practice. Other technical limitations
re being addressed through the evolution of radial equip-
ent, such as sheathless 7.5-F guiding catheters that allow
elected Transradial Challengesnd S rategie to Overcome ThemTable 3 Selected Tr nsradial Challengesand Strategies to Overcome Them
Patient setup
Prep wrist with patient’s arm at his or her side (radial artery parallel to
femoral artery)
Prep femoral artery simultaneously in case of crossover
Use either a rectangular platform or 2 “banjo” arm boards underneath
patient’s arm to create a working space distal to patient’s hand
Place towels on working space to elevate working space to level of wrist
For left radial cases, elevated left arm using pillows to bring left radial above
left groin or have patient bring left arm across body after obtaining left
radial artery access
Radial artery access
Small-caliber artery
Inject subcutaneous nitroglycerin
Check contralateral radial artery
Spasm
Intra-arterial nitroglycerin, calcium channel blockers
Patient sedation
Use smaller French size catheters
Repeat access
Check patency of artery (ultrasonography or reverse Allen test*); obtain
access more proximally
Traversing the radiobrachial region
Radiobrachial angiogram for any resistance to advancing the wire or catheter
Radial loop: use 0.014-inch hydrophilic wires to traverse and straighten loop
Consider femoral access bailout if unable to traverse radial loop or if there is
significant patient discomfort
Traversing the chest arteries
Have patient take a deep breath to straighten subclavian/innominate arteries
and subclavian/innominate-aortic junction to direct catheter to ascending
aorta
For extreme z-curves, use hydrophilic 0.035-inch wires to direct catheters into
ascending aorta
Engaging the coronary arteries
Judkins curves: use longer JR curve (e.g., JR5), shorter JL curve (e.g., JL3.5)
Specialized curves (e.g., Kimny, Tiger, Jacky, Ikari, Amplatz)
Previous CABG: use left wrist with JR4/JL4 catheters, multipurpose catheter,
or specialized curves
For reverse Allen test, occlude both radial and ulnar arteries, then release radial artery to
etermine presence of antegrade flow.
CABG  coronary artery bypass grafting.reater support and accommodate dual-stent techniques and iarger devices, but which create arteriotomies that are
maller than 6-F sheaths (48).
The compartmentalization of transradial PCI to a few
enters or operators has also limited the quality of data
upporting its use. Most of the studies reviewed in this
rticle are retrospective and observational and therefore
ubject to significant selection bias. Even when randomized
rials are performed, they are either single-center studies or
nclude only a few centers with high concentrations of
xperienced radialists. The practice of PCI has evolved to
nclude pharmacotherapy that reduces bleeding risk with the
ransfemoral approach (7) and very-low-profile coronary
evices that substantially improve the odds of procedural
uccess. In this context, unresolved issues related to tran-
radial PCI in the modern era include the true incidence of
adial artery occlusion and its clinical sequelae, re-access
f the radial artery for repeat procedures, the durability of
reviously accessed radial arteries as conduits for coronary
rtery bypass grafting, the utility of the Allen test in
reventing complications related to vascular compromise
fter transradial PCI, the true learning curve for transradial
CI including the rate of crossover to the transfemoral
pproach, the effect of the transradial approach on bleeding
nd “hard” clinical outcomes such as death or post-
rocedural stroke, the influence of transradial PCI on costs,
he safety of same-day discharge after transradial PCI, and
he advantages and disadvantages of the transradial ap-
roach for primary PCI for ST-segment elevation myocar-
ial infarction.
Although many of these topics have been addressed in
revious studies, none have been the focus of recent studies
hat take into account modern pharmacotherapy, patent
emostasis for post-procedural radial artery compression, or
he current attention on door-to-balloon times for primary
CI. Upcoming investigations capable of illuminating some
f these important issues are summarized in Table 4.
Another important contribution possible with wider ap-
lication of transradial PCI is the study and potential
pplication of higher doses of antithrombotics. Antithrom-
otic doses studied in phase 3 trials are often determined by
xamining complications that occur across a range of doses
xplored during phase 2 trials. The upper limit of dosing for
nticoagulants and parenteral antiplatelet agents commonly
sed in PCI is determined by bleeding complications, many
f which occur at the vascular access site. Figure 4 displays
he overall bleeding rates and proportion of bleeding related
o access site across a sampling of PCI, non–ST-segment
levation ACS, and ST-segment elevation myocardial in-
arction trials. The substantial reduction in access-site
leeding afforded by the transradial approach may allow
igher doses to be carried forward into phase 3 trials and
ltimately into clinical practice.
For example, current guidelines for dosing of unfraction-
ted heparin during PCI are based on data demonstrating
n association between higher activated clotting times and
ncreased bleeding events (49). However, some studies have
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Transradial Approach for PCI May 18, 2010:2187–95lso demonstrated an association between higher heparin
oses and reduced ischemic events (50). The transradial ap-
roach may allow a wider therapeutic index for anticoagulants
uch as unfractionated heparin—preserving ischemic reduction
ith higher doses while minimizing the penalty of increased
leeding.
onclusions
he evolution of PCI practice has led to an emphasis on
inimizing post-procedural vascular and bleeding compli-
ations while maintaining procedural success. A growing
ody of literature supports the use of the radial artery over
he femoral artery to achieve these goals, and data demon-
trate an association between the transradial approach and
educed costs and post-procedural LOS. Despite these
dvantages, there are some limitations to this approach,
uch as the potential impact on radial artery patency and
reater radiation exposure during the learning curve—a
actor that has limited adoption of this technique.
reater penetration of the transradial approach will
epend on the availability of educational programs for
nterventionalists and fellows-in-training, commitment
rom professional societies to support transradial PCI,
nd the generation of high-quality evidence to determine
ts comparative effectiveness against the traditional fem-
ral approach. Systematic use of the transradial approach
ay also affect drug development by allowing higher (and
otentially more efficacious) doses of anticoagulants to be
tudied in phase 3 trials and implemented in clinical
ractice.
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